Keytruda

Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report
Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report
Fierce Pharma
Merck
Keytruda
Bristol-Myers Squibb
Pfizer
Eliquis
AbbVie
Humira
Flag link:
Merck’s KEYTRUDA approved as monotherapy in China for first-line treatment of certain patients with advanced NSCLC
Merck’s KEYTRUDA approved as monotherapy in China for first-line treatment of certain patients with advanced NSCLC
Pharmaceutical Business Review
Merck
Keytruda
China
non-small cell lung cancer
Flag link:
ESMO: Merck, Eisai detail Keytruda-Lenvima combo results after triple endometrial cancer OK
ESMO: Merck, Eisai detail Keytruda-Lenvima combo results after triple endometrial cancer OK
Fierce Pharma
Merck
Eisai
Keytruda
Lenvima
endometrial cancer
ESMO
Flag link:
Merck, Pfizer execs explain how they tap sites for cancer trials
Merck, Pfizer execs explain how they tap sites for cancer trials
Biopharma Dive
cancer
clinical trials
Pfizer
Merck
immuno-oncology
Bavencio
Keytruda
Flag link:
Biotechs Fly Sideways In Quiet Week — 5 News Items You May Have Missed
Biotechs Fly Sideways In Quiet Week — 5 News Items You May Have Missed
Investors Business Daily
Wave Life Sciences
suvodirsen
DMD
Merck
Keytruda
Biogen
Spinraza
Zoetis
Europe
animal health
Jazz Pharmaceuticals
JZP-258
narcolepsy
Flag link:
The top drugs facing cuts under Pelosi's pricing plan
The top drugs facing cuts under Pelosi's pricing plan
Biopharma Dive
drug pricing
Nancy Pelosi
regulatory
Revlimid
Keytruda
Opdivo
Januvia
insulin
Medicare
Flag link:
Merck, Eisai's Keytruda-Lenvima combo wins simultaneous OKs in U.S., Canada and Australia
Merck, Eisai's Keytruda-Lenvima combo wins simultaneous OKs in U.S., Canada and Australia
Fierce Pharma
Merck
Keytruda
Eisai
Lenvima
endometrial cancer
Canada
Australia
Flag link:
Esmo 2019 preview – immunotherapies grab the rest of the late-breaker focus
Esmo 2019 preview – immunotherapies grab the rest of the late-breaker focus
EP Vantage
ESMO
Keytruda
Tecentriq
Merck
Roche
Flag link:
WCLC: Merck's Keytruda dispels 'urban legend' with latest lung cancer survival win
WCLC: Merck's Keytruda dispels 'urban legend' with latest lung cancer survival win
Fierce Pharma
Merck
Keytruda
non-small cell lung cancer
WCLC
Flag link:
At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More
At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More
Xconomy
WCLC
lung cancer
KRAS
AMG 510
Amgen
RET
Merck
Keytruda
AstraZeneca
Imfinzi
Blueprint Medicines
Eli Lilly
Flag link:
WCLC: Merck analyses throw doubt on new biomarker's utility
WCLC: Merck analyses throw doubt on new biomarker's utility
Fierce Pharma
Merck
biomarkers
TMB
Keytruda
Flag link:
Keytruda combo cleared as first-line kidney cancer treatment in EU
Keytruda combo cleared as first-line kidney cancer treatment in EU
Pharmaforum
Merck
Keytruda
kidney cancer
Europe
Flag link:
Merck’s Keytruda: A Deep Dive
Merck’s Keytruda: A Deep Dive
BioSpace
Merck
Keytruda
Flag link:
What happened a year ago this week in biopharma? August 12-18, 2018
Regeneron
Novartis
wet-AMD
Eylea
ethics
Vertex Pharmaceuticals
Kalydeco
cystic fibrosis
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
SCLC
Flag link:
What happened a year ago this week in biopharma? August 12-18, 2018
What happened a year ago this week in biopharma? August 12-18, 2018
CP WIre
Regeneron
Novartis
wet-AMD
Eylea
ethics
Vertex Pharmaceuticals
Kalydeco
cystic fibrosis
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
SCLC
Flag link:
How Merck Could Ride 'The Keytruda Wave' To Dominate These Rivals
How Merck Could Ride 'The Keytruda Wave' To Dominate These Rivals
Investors Business Daily
Merck
Keytruda
cancer
Flag link:
MSD’s Keytruda plus chemo backed by NICE for lung cancer
MSD’s Keytruda plus chemo backed by NICE for lung cancer
Pharmaforum
Merck
Keytruda
NICE
non-small cell lung cancer
Flag link:
Leap zeroes in on subgroup for DKN-01, Keytruda combo
Leap zeroes in on subgroup for DKN-01, Keytruda combo
BioCentury
Leap Therapeutics
DKN-01
Keytruda
gastric cancer
Flag link:
These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024
These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024
Yahoo/Motley Fool
Merck
Keytruda
AbbVie
Humira
Pfizer
Bristol-Myers Squibb
Eliquis
JNJ
Imbruvica
Flag link:
Merck's Keytruda makes the cut as a second-line monotherapy for certain esophageal cancer patients
Merck's Keytruda makes the cut as a second-line monotherapy for certain esophageal cancer patients
Endpoints
Merck
Keytruda
esophageal cancer
Flag link:

Pages